MiMedx Valuation
| MDXG Stock | USD 5.12 0.03 0.59% |
At this time, the firm appears to be undervalued. MiMedx Group secures a last-minute Real Value of $6.55 per share. The latest price of the firm is $5.12. Our model forecasts the value of MiMedx Group from analyzing the firm fundamentals such as return on equity of 0.19, and Profit Margin of 0.10 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting MiMedx's valuation include:
Price Book 3.2292 | Enterprise Value | Enterprise Value Ebitda 9.4828 | Price Sales 1.9612 | Forward PE 19.5313 |
Undervalued
Today
Please note that MiMedx's price fluctuation is somewhat reliable at this time. Calculation of the real value of MiMedx Group is based on 3 months time horizon. Increasing MiMedx's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the MiMedx stock is determined by what a typical buyer is willing to pay for full or partial control of MiMedx Group. Since MiMedx is currently traded on the exchange, buyers and sellers on that exchange determine the market value of MiMedx Stock. However, MiMedx's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.12 | Real 6.55 | Target 10.4 | Hype 5.03 |
The real value of MiMedx Stock, also known as its intrinsic value, is the underlying worth of MiMedx Group Company, which is reflected in its stock price. It is based on MiMedx's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of MiMedx's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of MiMedx Group helps investors to forecast how MiMedx stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of MiMedx more accurately as focusing exclusively on MiMedx's fundamentals will not take into account other important factors: When choosing an evaluation method for MiMedx Group, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
MiMedx Cash |
|
MiMedx Total Value Analysis
MiMedx Group is now anticipated to have valuation of 647.74 M with market capitalization of 771.61 M, debt of 24.84 M, and cash on hands of 72.5 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the MiMedx fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
647.74 M | 771.61 M | 24.84 M | 72.5 M |
MiMedx Investor Information
About 72.0% of the company shares are owned by institutional investors. The book value of MiMedx was now reported as 1.61. The company has Price/Earnings To Growth (PEG) ratio of 2.97. MiMedx Group had not issued any dividends in recent years. The entity had 3235:10000 split on the 2nd of April 2008. Based on the key measurements obtained from MiMedx's financial statements, MiMedx Group is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in March.MiMedx Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. MiMedx has an asset utilization ratio of 132.19 percent. This implies that the Company is making $1.32 for each dollar of assets. An increasing asset utilization means that MiMedx Group is more efficient with each dollar of assets it utilizes for everyday operations.MiMedx Profitability Analysis
Based on the key profitability measurements obtained from MiMedx's financial statements, MiMedx Group is yielding more profit at this time then in previous quarter. It has a moderate odds of reporting better profitability numbers in March. Profitability indicators assess MiMedx's ability to earn profits and add value for shareholders.Net Income | First Reported 2007-03-31 | Previous Quarter 9.6 M | Current Value 16.7 M | Quarterly Volatility 2 B |
For MiMedx profitability analysis, we use financial ratios and fundamental drivers that measure the ability of MiMedx Group to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well MiMedx utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between MiMedx's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of MiMedx over time as well as its relative position and ranking within its peers.
MiMedx Earnings per Share Projection vs Actual
The next projected EPS of MiMedx is estimated to be 0.03 with future projections ranging from a low of 0.03 to a high of 0.03. MiMedx's most recent 12-month trailing earnings per share (EPS TTM) is at 0.27. Please be aware that the consensus of earnings estimates for MiMedx Group is based on EPS before non-recurring items and includes expenses related to employee stock options.MiMedx Earnings Estimation Breakdown
The calculation of MiMedx's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of MiMedx is estimated to be 0.03 with the future projection ranging from a low of 0.03 to a high of 0.03. Please be aware that this consensus of annual earnings estimates for MiMedx Group is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.03 Lowest | Expected EPS | 0.03 Highest |
MiMedx Earnings Projection Consensus
Suppose the current estimates of MiMedx's value are higher than the current market price of the MiMedx stock. In this case, investors may conclude that MiMedx is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and MiMedx's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 5 | 66.04% | 0.0 | 0.03 | 0.27 |
MiMedx Ownership Allocation
MiMedx Group maintains a total of 148.1 Million outstanding shares. The majority of MiMedx outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in MiMedx Group to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in MiMedx Group. Please pay attention to any change in the institutional holdings of MiMedx as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.MiMedx Profitability Analysis
The company reported the previous year's revenue of 348.88 M. Net Income was 42 M with profit before overhead, payroll, taxes, and interest of 322.58 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates MiMedx's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in MiMedx and how it compares across the competition.
About MiMedx Valuation
The stock valuation mechanism determines MiMedx's current worth on a weekly basis. Our valuation model uses a comparative analysis of MiMedx. We calculate exposure to MiMedx's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of MiMedx's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 332.1 M | 196.4 M | |
| Pretax Profit Margin | 0.15 | 0.16 | |
| Operating Profit Margin | 0.15 | 0.16 | |
| Net Profit Margin | 0.12 | 0.11 | |
| Gross Profit Margin | 0.75 | 0.56 |
MiMedx Growth Indicators
Investing in growth stocks can be very risky. If the company such as MiMedx does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 149 M | |
| Quarterly Earnings Growth Y O Y | 1.138 | |
| Forward Price Earnings | 19.5313 |
MiMedx Current Valuation Indicators
Valuation refers to the process of determining the present value of MiMedx Group and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value MiMedx we look at many different elements of the entity such as MiMedx's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as MiMedx, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use MiMedx's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes MiMedx's worth.Complementary Tools for MiMedx Stock analysis
When running MiMedx's price analysis, check to measure MiMedx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MiMedx is operating at the current time. Most of MiMedx's value examination focuses on studying past and present price action to predict the probability of MiMedx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MiMedx's price. Additionally, you may evaluate how the addition of MiMedx to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |